Compare KKR & Co Inc (KKR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KKR & Co Inc vs Sanofi SA — how do they compare? KKR & Co Inc trades at $90.95 (market cap $80.39B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold KKR & Co Inc for 67 Days and Sanofi SA for 94 Days on average.
| KKR | SNY | |
|---|---|---|
Market Cap | $80.39B | $95.18B |
Volume | 6,517,705 | 2,995,646 |
Sector | Financials | Health |
52-Week High | $142.75 | $52.34 |
52-Week Low | $83.88 | $39.51 |
Typical Hold Time | 67 Days | 94 Days |
Enterprise Value | $2.95B | $114.48B |
Dividend Yield | 0.87% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KKR trades at $89.56, down 0.12% with bearish technical signals despite strong analyst support. The company reported mixed quarterly results with Q2 2026 EPS beating expectations at $1.63 versus $1.43 estimate, while Q4 2025 missed. Recent business activity includes joint ventures with Thomson Reuters and Realty Income, plus multiple asset sales in Asia. Financial trends show revenue stabilizing around $19-21B with net margins improving to 14.96% projected for 2026.
The investment case balances strong Wall Street bullishness (88.9% buy ratings, $123.30 consensus target) against technical weakness and volatile cash flows. Key opportunities include continued earnings beats and strategic partnerships, while risks involve significant debt levels and market-sensitive investment returns. The stock presents a value gap if fundamentals can overcome current technical pressure.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
